Effect of White Button Mushroom in treatment of diabetic patients with type 2 diabetes mellitus

A Clinical trail to compare White Button Mushroom (Agaricus Bisporus) powder with corn starch on levels of glycemic indices, lipid profile , serum hs - CRP, ergothioneine and total antioxidant capacity in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017062534760N1

Enrollment

Registered

2017-09-27

Start date

2017-04-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention: The intervention group receive 16 gr mushroom powder twice a day with food (8 grams per meal), daily for 8 weeks. Intervention 2: Control: The control group receive 16 gr

Placebo

Intervention: The intervention group receive 16 gr mushroom powder twice a day with food (8 grams per meal), daily for 8 weeks.

Control: The control group receive 16 gr corn starch powder twice a day with food (8 grams per meal), daily for 8 weeks

Eligibility

Sex/Gender

All

Age

23 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: type 2 diabetic patients who have been suffering from the disease for at least 2 years and have been using diabetic drugs for more than 6 month; BMI between 20 and 35 kg/m2. Exclusion criteria: using insulin therapy; Smoking; pregnancy; breast feeding; Weight loss greater than 10% of body weight in the past 6 months; being currently on a weight-loss diet or program; allergic to latex; allergic to mushrooms; consuming mushroom more than once or twice a week; major medical conditions (such as renal failure, heart failure, inflammatory diseases, hepatitis); using immunosuppressive; NSAIDs; diuretic; estrogen medications; using any dietary supplements including antioxidant, fiber, omega 3.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Insulin. Timepoint: before and after intervention. Method of measurement: ElISA.;Fructosamine. Timepoint: before and after intervention. Method of measurement: ElISA.;LDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;HDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;VLDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Triglyceride. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Total cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Hs-CRP. Timepoint: before and after intervention. Method of measurement: ElISA.;TAC. Timepoint: before and after intervention. Method of measurement: ElISA.;Ergothioneine. Timepoint: before and after intervention. Method of measurement: HPLC.	—

Measure

Time frame

Fasting blood glucose. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Insulin. Timepoint: before and after intervention. Method of measurement: ElISA.;Fructosamine. Timepoint: before and after intervention. Method of measurement: ElISA.;LDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;HDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;VLDL cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Triglyceride. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Total cholestrol. Timepoint: before and after intervention. Method of measurement: Using enzymatic kit method.;Hs-CRP. Timepoint: before and after intervention. Method of measurement: ElISA.;TAC. Timepoint: before and after intervention. Method of measurement: ElISA.;Ergothioneine. Timepoint: before and after intervention. Method of measurement: HPLC.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadiseh Hashemi yusefabad

Ahvaz Jundishapur University of Medical Science

hashemihadis@yahoo.com+98 61 1333 3050

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026